BVF Partners Exits XOMA Royalty Corp: What It Means for Investors and Healthcare Trends
BVF Partners’ $39 cash exit from XOMA Royalty Corp shows a profit‑taking, value‑play trend, highlighting the role of CVRs, shifting ownership, and potential upside in biotech royalty assets.
4 minutes to read